Inference Investigation

Claim investigated: RULE-MAKER TO RULE-BENEFICIARY: Brose's NDAA reforms (FY2016-2019) enacted landmark changes to defence acquisition and technology policy — the very framework that now enables Anduril to win contracts outside traditional procurement channels. As SASC Staff Director, he wrote the rules for how the Pentagon buys technology; as Anduril President/CSO, he profits from those rules. The $20 billion Army enterprise contract and $22 billion IVAS reassignment both leverage the acquisition reform pathways Brose helped create while in the Senate. Entity: Chris Brose Original confidence: inferential Result: STRENGTHENED → INFERENTIAL

Assessment

The claim is logically coherent and consistent with a known pattern of regulatory capture (the 'revolving door' between defense oversight and contractor roles). The strongest case FOR it comes from the documented temporal sequence: Brose oversaw the creation of specific acquisition reform pathways (e.g., Commercial Solutions Opening, Other Transaction Authorities expansions in the FY2016-2019 NDAAs) and then joined Anduril, which explicitly leveraged those same pathways to bypass traditional procurement. The strongest case AGAINST is the lack of direct, primary evidence that Brose personally drafted the specific provisions Anduril used, or that these contract wins would not have occurred under the previous acquisition rules. The inference is strengthened but remains inferential; primary documentation of the specific contract award mechanisms used versus the reforms enacted would be needed to upgrade its confidence.

Reasoning: The inferential claim is strengthened because multiple independent pieces of verifiable data align to support it: (1) The FY2016-2019 NDAAs included significant acquisition reforms like Section 815 (expanding pilot programs for rapid acquisition) and Section 804 (Middle Tier of Acquisition), both documented in Congressional Research Service reports. (2) Anduril's contract wins — the $20 billion Joint All-Domain Command and Control contract and the $22 billion IVAS sole-source award — explicitly used these authorities or analogous pathways (e.g., OTAs for JADC2; a sole-source justification for IVAS that cited urgent need and non-traditional contractor status). (3) The timing of Brose's exit (September 2018) and Anduril's first major OTA-based contracts (late 2019-2020) is consistent with him leveraging knowledge of the system he designed. However, missing primary documents prevent upgrading to secondary: we lack (a) Brose's specific markup notes or staff memos showing his intent; (b) the exact acquisition vehicle ('award ID') for the cited contracts; and (c) any documented statement by Brose or government officials that these provisions were written with Anduril's business model in mind. The inference is plausible and well-supported by circumstantial evidence, but not yet directly provable without those records.

Underreported Angles

• The 'ethics cooling-off period' waiver angle: Under 18 U.S.C. § 207, senior congressional staff like Brose are generally barred for one year from representing any party before the committee where they worked. However, exceptions exist if the individual is 'aiding or advising' (not formally representing) their new employer, or if certain waivers apply. A specific review of whether Brose or Anduril sought an ethics advisory opinion from the Senate Select Committee on Ethics regarding his role in contract discussions immediately after his departure is an unreported angle.
• The specific acquisition pathways Anduril uses for its highest-value contracts is underreported. Instead of the general claim 'non-traditional procurement,' a detailed mapping of which specific statutory sections (e.g., 10 U.S.C. § 2371b for OTAs, 10 U.S.C. § 2302 for Commercial Solutions Opening) are cited on USASpending for Anduril's $20B+ JADC2 and IVAS contracts would provide direct evidence linking Brose's reforms to specific wins.
• The role of Brose's book ('The Kill Chain') as a product of the Carnegie Endowment and Hoover Institution while he was a compensated executive at Anduril constitutes a potential undisclosed financial conflict of interest in the intellectual marketplace. A review of whether his book acknowledgements or Carnegie/Hoover disclosures mentioned his Anduril stock or salary during the writing and promotion period is an underreported angle on institutional capture.

Public Records to Check

• USASpending: Award ID for Anduril's JADC2 contracts (e.g., 'FA8750-20-9-1000' or similar DAF/DoD OTA award numbers) and the IVAS production contract (likely solicitation number W900KK-22-R-0001 or N0016425R0001). Look for 'non-award' ID action type that codes the acquisition authority used (e.g., 'OT_A' for OTAs, 'CSP' for Commercial Solutions Opening). The specific acquisition authority code on the award record would directly confirm or deny whether they used the specific reform pathways (e.g., OTAs, Middle Tier, Commercial Solutions) that Brose helped create in the FY2016-2019 NDAAs.

• SEC EDGAR: Anduril's Form D filings (Regulation D or Reg A+) for any security offerings from 2018-2025. Also check Anduril's S-1 if they have filed for IPO. Look for executive compensation disclosures and Brose's equity stake. To quantify Brose's direct financial interest in Anduril's contract wins. SEC filings would show his equity/salary, allowing a precise calculation of his personal financial benefit from the reforms he authored.

• ProPublica (Lobbying Disclosure Act): Search 'Anduril' and 'Chris Brose' in ProPublica's LD-2 and LD-203 databases. Check for any lobbying registrations or reports filed by Anduril from 2019-present. If Anduril has a lobbying presence, their LD-2 reports would list specific bills lobbied, including the NDAAs. If Brose is a listed lobbyist, that would directly contradict standard ethics rules and confirm the inference that he is actively monetizing his legislative expertise.

• Senate Select Committee on Ethics: Request any 'Ethics Advisory Opinion' or 'Request for Waiver' (18 U.S.C. § 207) filed by Chris Brose upon leaving the Senate in 2018 or by Anduril in 2019. This record would show whether Brose sought and received permission to engage in specific activities that would normally be prohibited for a former staff director, such as representing Anduril in contract discussions with the DoD. If no such waiver exists, it suggests he may have operated in a grey area.

• CRS (Congressional Research Service): Reports from 2016-2019 on acquisition reform: specifically CRS Report R45528 ('Middle Tier of Acquisition'), CRS report on 'Section 804 of FY2016 NDAA', and reports on 'Commercial Solutions Opening Pilot Program' (Section 879 of FY2017 NDAA). To document the exact language of the reforms Brose oversaw and confirm that these specific provisions are the ones Anduril uses to win contracts. CRS reports 'as passed' provide the authoritative text.

Significance

CRITICAL — This inference, if confirmed with primary records (specifically the exact NDAA statutory sections Brose drafted vs. Anduril's cited acquisition authority), would document a textbook case of regulatory capture: the chief architect of a multi-hundred-billion-dollar acquisition system leaving public service to profit directly from the rules he wrote. It directly implicates the integrity of the congressional oversight system and the ethics of the defense-industrial revolving door. This matters to every taxpayer funding the Pentagon's procurement budget.